VBLT - VBL Therapeutics GAAP EPS of -$0.12 in-line revenue of $0.5M beats by $0.3M
- VBL Therapeutics press release ( NASDAQ: VBLT ): Q3 GAAP EPS of -$0.12 in-line.
- Revenue of $0.5M (+150.0% Y/Y) beats by $0.3M .
- At September 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $27.7M.
- VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least twelve months.
For further details see:
VBL Therapeutics GAAP EPS of -$0.12 in-line, revenue of $0.5M beats by $0.3M